Use: Labeled indications
- VERMOX™ CHEWABLE is indicated for the treatment of patients one year of age and older with gastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm).
Full indications and usage US FDA label
1 INDICATIONS AND USAGE VERMOX™ CHEWABLE is indicated for the treatment of patients one year of age and older with gastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm). VERMOX™ CHEWABLE is an anthelmintic indicated for the treatment of patients one year of age and older with gastrointestinal infections caused by: Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm) (1).
Contraindications
4 CONTRAINDICATIONS VERMOX™ CHEWABLE is contraindicated in persons with a known hypersensitivity to the drug or its excipients. Patients with a known hypersensitivity to the drug or its excipients (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION The recommended dosage in patients one year of age and older is one VERMOX™ CHEWABLE 500 mg tablet taken as a single dose. Chew VERMOX™ CHEWABLE 500 mg tablet completely before swallowing. Do not swallow the tablet whole. For patients who have difficulty chewing the tablet, approximately 2 mL to 3 mL of drinking water can be added to a suitably sized spoon and the VERMOX™ CHEWABLE 500 mg tablet placed into the water.
Within 2 minutes, the tablet absorbs the water and turns into a soft mass with semi-solid consistency, which can then be swallowed. VERMOX™ CHEWABLE 500 mg tablet can be taken without regard to food intake [see Clinical Pharmacology (12.3)]. The recommended dosage in patients one year of age and older is one single tablet of VERMOX™ CHEWABLE 500 mg taken as a single dose, chewed completely before swallowing (2).
See Full Prescribing Information for administration instructions for patients who have difficulty chewing the tablets (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of VERMOX™ CHEWABLE 500 mg tablets have been established in pediatric patients 1 to 16 years of age. Use of VERMOX™ CHEWABLE 500 mg tablets in children is supported by evidence from adequate and well-controlled studies of VERMOX™ CHEWABLE 500 mg tablets [see Clinical Studies (14)].
The safety and effectiveness of mebendazole, including VERMOX™ CHEWABLE have not been established in pediatric patients less than one year of age. Convulsions have been reported with mebendazole use in this age group [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of mebendazole did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.
Dosage forms
Philippines
- Tablet: 100 mg, 500 mg
- Chewable tablet: 500 mg
- Suspension: 100 mg/5 mL
- ) suspension: 20 mg/mL (100 mg/5 mL
Registered products in the Philippines
14 products registered with the Food and Drug Administration (FDA) Philippines list Mebendazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products14
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AntioxMebendazole | 20 mg/mL (100 mg/5 mL) SuspensionType III Moulded Amber Glass Bottle x 30 mL with Child-resistant Screw Cap Closure and Measuring Cup (Box of 1's) | OTC | Janssen Pharmaceutica N.V.Belgium | Zuellig Pharma CorporationImporter: Johnson & Johnson (Philippines), Inc. | DR-X3594 | May 10, 2031 | |
AntioxMebendazole | 500 mg Chewable TabletClear PVC-Alu Blister pack of 4’s Box of 36’s | OTC | Janssen Korea Ltd.Republic of Korea | Zuellig Pharma CorporationImporter: Johnson & Johnson (Philippines), Inc. | DR-XY40801 | Apr 2, 2027 | |
AntioxMebendazole | 500 mg TabletClear PVC/Alu Blister Pack x 4's Box of 100's; Clear PVC/Alu Blister Pack x 1'S Box of 1's | Rx | Lusomedicamenta Sociedade Tecnica Farmaceutica, S.A.Portugal | Importer: Johnson & Johnson (Philippines), Inc.Trader: Janssen-Cilag AG | DR-XY46744 | Oct 10, 2029 | |
KhrizverMebendazole | 500 mg Chewable Tablet (Orange Flavor)Alu/PVC Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | Khriz Pharma Trading Inc. | DRP-10463 | Sep 29, 2036 | |
KhrizverMebendazole | 500mg Chewable Tablet (Orange Flavor)Alu/PVC Blister Pack x 10's (Box of 100's) | OTC | Fredun Pharmaceuticals LimitedIndia | Khriz Pharma Trading, Inc. | DRP-11037 | Jan 12, 2027 | |
MebazaMebendazole | 500 mg Chewable Tablet (Orange Flavor)Alu/PVC Blister Pack x 10's (Box of 10's & 100's) | OTC | Huazhong Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17066 | Sep 24, 2030 | |
NoneMebendazole | 100 mg/5 mL SuspensionBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-5663 | May 24, 2030 | |
NoneMebendazole | 100mg/5mL SuspensionAmber glass bottle x 30mL and 60mL (Box of 1's) | Rx | LEJAL LABORATORIES INC.Philippines | — | DR-XY11331 | Dec 11, 2027 | |
NoneMebendazole | 500 mg tabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Scheele Laboratories Phils., Inc.Philippines | — | DRP-3240 | Sep 12, 2029 | |
NoneMebendazole | 500 mg TabletBlister Pack x 10's Box of 100's | OTC | Drugmaker's Laboratories Inc.Philippines | — | DRP-5667 | May 18, 2030 | |
SaphbenzaMebendazole | 500 mg TabletAlu/PVC Blister Pack x 10’s (Box of 30’s and 100’s) | OTC | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-18732 | Aug 27, 2031 | |
UnbrandedMebendazole | 100 mg/5 mL Suspension (Banana Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL (Box of 1's) | OTC | Scheele Laboratories Phils., Inc.Metro Manila | — | DRP-3233 | Sep 7, 2031 | |
UnbrandedMebendazole | 100mg TabletAlu/Clear PVC Blister pack x 10's (Box of 100''s) | OTC | Drugmaker's Laboratories Inc.Laguna | — | DRP-5850 | Jul 29, 2031 | |
ZolmintMebendazole | 100 mg / 5 mL Suspension (Banana Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL (Box of 1's) | OTC | Scheele Laboratories Phils., Inc.Metro Manila | Zeutica, Inc. | DRP-3233-03 | Sep 7, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Chewable Tablet: 500 mg round, flat radius-edged white to yellowish chewable tablet that is debossed with "M/500" on one side and "J" on the other side. Chewable Tablet: 500 mg (3)
Warnings/Precautions
- Risk of Convulsions: Convulsions in infants below the age of 1 year have been reported (5.1)
- Hematologic Effects: Neutropenia and agranulocytosis have been reported in patients receiving mebendazole at higher doses and for prolonged duration. Monitor blood counts in these patients (5.2)
- Metronidazole and Serious Skin Reactions: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have been reported with the concomitant use of mebendazole and metronidazole. Avoid concomitant use of mebendazole and metronidazole (5.3)
5.1 Risk of Convulsions
5.1 Risk of Convulsions Convulsions have been reported in infants below the age of 1 year during post-marketing experience with mebendazole [see Adverse Reactions (6.2)].
5.2 Hematologic Effects
5.2 Hematologic Effects Agranulocytosis and neutropenia have been reported with mebendazole use at higher doses and for more prolonged durations than is recommended for the treatment of soil-transmitted helminth infections. Monitor blood counts if VERMOX™ CHEWABLE is used at higher doses or for prolonged duration.
5.3 Metronidazole Drug Interaction and Serious Skin Reactions
5.3 Metronidazole Drug Interaction and Serious Skin Reactions Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have been reported with the concomitant use of mebendazole and metronidazole. Avoid concomitant use of mebendazole and metronidazole.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Concomitant use of mebendazole and metronidazole should be avoided [see Warnings and Precautions (5.3)].
Adverse reactions
Adverse reactions reported in clinical trials were anorexia, abdominal pain, diarrhea, flatulence, nausea, vomiting and rash. (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Studies
6.1 Clinical Studies Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of mebendazole was evaluated in 6276 adult and pediatric subjects one year of age and older who participated in 39 clinical trials for treatment of single or mixed parasitic infections of the gastrointestinal tract.
In these trials, the formulations, dosages and duration of mebendazole treatment varied. Adverse reactions reported in mebendazole-treated subjects from the 39 clinical trials are shown in Table 1 below. Table 1: Adverse Reactions Reported in Mebendazole-Treated Subjects from 39 Clinical Trials Includes mebendazole formulations, dosages and treatment duration other than VERMOX™ CHEWABLE 500 mg tablet Adverse Reaction(s) Gastrointestinal Disorders Anorexia Abdominal Pain Diarrhea Flatulence Nausea Vomiting Skin and Subcutaneous Tissue Disorders Rash Clinical Studies with Mebendazole Chewable 500 mg Tablet The safety profile of mebendazole chewable 500 mg tablets administered as a single dose was evaluated in 677 pediatric subjects aged 1 to 16 years and in 34 adults.
The safety profile was consistent with the known safety profile of mebendazole.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified in adult and pediatric patients postmarketing with mebendazole formulations and dosages other than the VERMOX™ CHEWABLE 500 mg tablet. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Table 2: Adverse Reactions Identified During Postmarketing Experience with Mebendazole Includes mebendazole formulations, dosages and treatment durations other than VERMOX™ CHEWABLE 500 mg tablet Adverse Reaction(s) Blood and Lymphatic System Disorders Agranulocytosis, Neutropenia Immune System Disorders Hypersensitivity including anaphylactic reactions Nervous System Disorders Convulsions, Dizziness Hepatobiliary Disorders Hepatitis, Abnormal liver tests Renal and Urinary Disorders Glomerulonephritis Skin and Subcutaneous Tissue Disorders Toxic epidermal necrolysis, Stevens-Johnson syndrome, Exanthema, Angioedema, Urticaria, Alopecia
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction(s) |
|---|
| Gastrointestinal Disorders |
| Anorexia |
| Abdominal Pain |
| Diarrhea |
| Flatulence |
| Nausea |
| Vomiting |
| Skin and Subcutaneous Tissue Disorders |
| Rash |
| Adverse Reaction(s) | |
|---|---|
| Blood and Lymphatic System Disorders | Agranulocytosis, Neutropenia |
| Immune System Disorders | Hypersensitivity including anaphylactic reactions |
| Nervous System Disorders | Convulsions, Dizziness |
| Hepatobiliary Disorders | Hepatitis, Abnormal liver tests |
| Renal and Urinary Disorders | Glomerulonephritis |
| Skin and Subcutaneous Tissue Disorders | Toxic epidermal necrolysis, Stevens-Johnson syndrome, Exanthema, Angioedema, Urticaria, Alopecia |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary The available published literature on mebendazole use in pregnant women has not reported a clear association between mebendazole and a potential risk of major birth defects or miscarriages [see Data]. There are risks to the mother and fetus associated with untreated helminthic infection during pregnancy [see Clinical Considerations].
In animal reproduction studies, adverse developmental effects (i.e., skeletal malformations, soft tissue malformations, decreased pup weight, embryolethality) were observed when mebendazole was administered to pregnant rats during the period of organogenesis at single oral doses as low as 10 mg/kg (approximately 0.2-fold the maximum recommended human dose (MRHD)). Maternal toxicity was present at the highest of these doses [see Data].
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risks Untreated soil-transmitted helminth infections in pregnancy are associated with adverse outcomes including maternal iron deficiency anemia, low birth weight, neonatal and maternal death. Data Human Data Several published studies, including prospective pregnancy registries, case-control, retrospective cohort, and randomized controlled studies, have reported no association between mebendazole use and a potential risk of major birth defects or miscarriage.
Overall, these studies did not identify a specific pattern or frequency of major birth defects with mebendazole use. However, these studies cannot definitely establish the absence of any mebendazole-associated risk because of methodological limitations, including recall bias, confounding factors and, in some cases, small sample size or exclusion of first trimester mebendazole exposures.
Animal Data Embryo-fetal developmental toxicity studies in rats revealed no adverse effects on dams or their progeny at doses up to 2.5 mg/kg/day on gestation days 6–15 (the period of organogenesis). Dosing at ≥10 mg/kg/day resulted in a lowered body weight gain and a decreased pregnancy rate. Maternal toxicity, including body weight loss in one animal and maternal death in 11 of 20 animals, was seen at 40 mg/kg/day.
At 10 mg/kg/day, increased embryo-fetal resorption (100% were resorbed at 40 mg/kg/day), decreased pup weight and increased incidence of malformations (primarily skeletal) were observed. Mebendazole was also embryotoxic and teratogenic in pregnant rats at single oral doses during organogenesis as low as 10 mg/kg (approximately 0.2-fold the MRHD, based on mg/m 2).
In embryo-fetal developmental toxicity studies in mice dosed on gestation days 6–15, doses of 10 mg/kg/day and higher resulted in decreased body weight gain at 10 and 40 mg/kg/day and a higher mortality rate at 40 mg/kg/day. At doses of 10 mg/kg/day (approximately 0.1-fold the MRHD, based on mg/m 2) and higher, embryo-fetal resorption increased (100% at 40 mg/kg) and fetal malformations, including skeletal, cranial, and soft tissue anomalies, were present.
Dosing of hamsters and rabbits did not result in embryotoxicity or teratogenicity at doses up to 40 mg/kg/day (0.6 to 1.6-fold the MRHD, based on mg/m 2). In a peri- and post-natal toxicity study in rats, mebendazole did not adversely affect dams or their progeny at 20 mg/kg/day. At 40 mg/kg (0.8-fold the MRHD, based on mg/m 2), a reduction of the number of live pups was observed and there was no survival at weaning.
No abnormalities were found on gross and radiographic examination of pups at birth.
Mechanism of action
12.1 Mechanism of Action Mebendazole, a benzimidazole, is an anthelmintic [see Microbiology (12.4)].
US FDA labelPharmacokinetics
The apparent elimination half-life after an oral dose ranges from 3 to 6 hours in most patients.
Less than 2% of orally administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or its metabolites.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Following oral administration of VERMOX™ CHEWABLE 500 mg tablet, the majority of the dose remains in the gastrointestinal tract where it exerts an anthelmintic effect locally. Dosing the VERMOX™ CHEWABLE 500 mg tablet with a high fat meal increases the bioavailability of mebendazole. In the clinical studies conducted in pediatric patients with soil transmitted helminth infections, the majority of these patients were administered VERMOX™ CHEWABLE 500 mg tablets with food.
Mean plasma pharmacokinetic parameters of mebendazole in healthy adult subjects under fasted and fed conditions are summarized in Table 3. Table 3: Mean (SD) Plasma Pharmacokinetic Parameters After a Single VERMOX™ CHEWABLE 500 mg Dose in Healthy Adult Subjects (n=16) Under Fasted and Fed (High-fat Meal) Conditions Parameter Fasted Fed C max (ng/mL) 14.0 (9.17) 56.2 (35.8) T max (h) median (range) 1.5 (0.5–3.0) 4.0 (2.0–6.0) AUC last (ng.h/mL) 175 (129) 456 (249) Distribution The plasma protein binding of mebendazole is 90 to 95%.
The volume of distribution is 1 to 2 L/kg, indicating that absorbed mebendazole penetrates areas outside the vascular space. Metabolism Orally administered mebendazole is extensively metabolized primarily by the liver. Plasma concentrations of its major metabolites (hydrolyzed and reduced forms of mebendazole) are higher than those of mebendazole.
Impaired hepatic function, impaired metabolism, or impaired biliary elimination may lead to higher plasma levels of mebendazole. Elimination Mebendazole, the conjugated forms of mebendazole, and its metabolites likely undergo some degree of enterohepatic recirculation. The apparent elimination half-life after an oral dose ranges from 3 to 6 hours in most patients.
Less than 2% of orally administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or its metabolites. Specific Populations Pediatric Based on a limited number of blood samples, the pharmacokinetic results following single-dose administration of a 500 mg mebendazole chewable tablet to pediatric patients (age 1 to 16 years) with single or mixed infections of T. trichiura and/or A. lumbricoides indicated that children aged 1 to 3 years have higher systemic exposure than adults.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Mebendazole 100 mg/5 mL, 60 mL Suspension | ₱14.00–₱28.00Reference ₱14.00 | per unit | DPRI procurement range |
| Mebendazole 500 mg Tablet | ₱1.75–₱4.00Reference ₱1.75 | per tablet | DPRI procurement range |
| 50 mg/mL suspension in 10 mL | ₱127.00 | per unit | PhilHealth GAMOT fixed fee |
| 100 mg capsule | ₱6.00 | per capsule | PhilHealth GAMOT fixed fee |
| 100 mg tablet | ₱6.00 | per tablet | PhilHealth GAMOT fixed fee |
| 100 mg/5 mL suspension in 30 mL | ₱305.00 | per unit | PhilHealth GAMOT fixed fee |
| 100 mg/5 mL suspension in 60 mL | ₱40.75 | per unit | PhilHealth GAMOT fixed fee |
| 500 mg chewable tablet | ₱11.25 | per tablet | PhilHealth GAMOT fixed fee |
| 500 mg tablet | ₱41.50 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Mebendazole |
| PNF listing | Oral: 100 mg tablet/capsule |
| PNF listing | Oral: 500 mg tablet/chewable tablet |
| PNF listing | Oral: 50 mg/mL suspension, 10 mL |
| PNF listing | Oral: 100 mg/5 mL suspension, 30 mL and 60 mL |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. VERMOX · Janssen Pharmaceuticals, Inc. [US FDA-approved label, version 5, October 5, 2021]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a720c424-517a-461b-8e13-6c37caf8aa3f
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .